MRA (Tocilizumab) ( DrugBank: Tocilizumab )


2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
46悪性関節リウマチ4
107若年性特発性関節炎1

46. 悪性関節リウマチ


臨床試験数 : 4,356 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00144534
(ClinicalTrials.gov)
June 20042/9/2005Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA213JPAn Open-label, Extension, Phase III Study to Evaluate the Long-term Safety and Efficacy of MRA in Patients With RA Who Participated in Study MRA213JPRheumatoid ArthritisDrug: MRA (Tocilizumab)Chugai PharmaceuticalNULLCompleted20 Years75 YearsBoth115Phase 3NULL
2NCT00144508
(ClinicalTrials.gov)
March 20032/9/2005Phase III Comparative Study(Open-Label) of MRA for Rheumatoid Arthritis(RA)An Open-Label, Phase III Study to Evaluate the Efficacy and Safety of MRA in Patients With RARheumatoid ArthritisDrug: MRA (Tocilizumab);Other: current treatmentChugai PharmaceuticalNULLCompleted20 YearsN/ABoth306Phase 3NULL
3JPRN-JapicCTI-050016
02/09/2005A controlled, randomized trial of MRA monotherapy in patients with rheumatoid arthritis(RA)A controlled, randomized trial of MRA monotherapy in patients with rheumatoid arthritis(RA) RAIntervention name : MRA (tocilizumab)
Dosage And administration of the intervention : Intravenous infusion
Chugai Pharmaceutical Co., Ltd.NULL20Phase 3NULL
4JPRN-JapicCTI-050018
02/09/2005Double-blind, parallel-group, controlled Phase 3 study of MRA in rheumatoid arthritis(RA)Double-blind, parallel-group, controlled Phase 3 study of MRA in rheumatoid arthritis(RA) RAIntervention name : MRA (tocilizumab)
Dosage And administration of the intervention : Intravenous infusion
Chugai Pharmaceutical Co., Ltd.NULL2074Phase 3NULL

107. 若年性特発性関節炎


臨床試験数 : 447 薬物数 : 297 - (DrugBank : 57) / 標的遺伝子数 : 52 - 標的パスウェイ数 : 146
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-JapicCTI-050017
02/09/2005Phase 3 clinical study of MRA in patients with systemic juvenile idiopathic arthritis (sJIA)Phase 3 clinical study of MRA in patients with systemic juvenile idiopathic arthritis (sJIA) sJIAIntervention name : MRA (tocilizumab)
Dosage And administration of the intervention : Intravenous infusion
Chugai Pharmaceutical Co., Ltd.NULL219Phase 3NULL